China’s fragmented pharmaceutical industry is expected to undergo a wave of consolidation over the next five years, thanks to more stringent drug quality regulations and a reduction in layers of distribution intermediaries, according to Credit Suisse. Photo: Shutterstock 

Why most small players may not survive China’s pharmaceutical industry consolidation 

Strategy aims to turn China’s predominantly off-patent drug copying pharmaceutical industry into one that’s capable of coming up with innovative patentable products

Topic |   Health in China

TOP PICKS

China’s fragmented pharmaceutical industry is expected to undergo a wave of consolidation over the next five years, thanks to more stringent drug quality regulations and a reduction in layers of distribution intermediaries, according to Credit Suisse. Photo: Shutterstock 
READ FULL ARTICLE
Eric Ng

Eric Ng

Eric joined the SCMP in 1998 after brief stints in a trading company and translation and editing roles at Dow Jones and Edinburgh Financial Publishing. He has close to 20 years of experience covering China's energy, mining and industrial materials sectors, and has recently added biotechnology to his coverage. Eric has a Masters of Business Administration degree.